Evan T. Leo

I'll research this attorney before writing the summary.

Let me check the firm bio page and case outcomes.

Specialty / focus. Evan T. Leo is a Washington, D.C. litigator whose patent work sits alongside a large telecommunications regulatory practice. His firm biography describes patent and antitrust litigation for technology companies in federal courts and at the ITC, with named patent matters including Verizon v. Cablevision (ITC) and TiVo v. Verizon (E.D. Tex.), plus ITC patent enforcement for Corning. The single tracked case here is pharmaceutical rather than telecom: he appears as lead counsel for Regeneron in Regeneron Pharmaceuticals, Inc. v. Sandoz Inc., a BPCIA biosimilar action over aflibercept (Eylea). Third-party docket-aggregation data (Ex Parte's attorney profile, a commercial database rather than a court or firm source) lists his patent case mix as concentrated in communications (17 cases) and computer architecture/software (12), with smaller counts in semiconductor/optical, software/security, and mechanical arts — useful as directional color but not independently verified.

Side preference. The tracked data is thin: one appearance, plaintiff side, zero defendant side. That single matter is patent-owner enforcement — Regeneron asserting its own biologic patents against a biosimilar manufacturer. The broader public record is more mixed than that count suggests: the same firm bio highlights defense-side work (representing major carriers and equipment manufacturers, and defending Meta in FTC v. Meta Platforms and the Within Unlimited acquisition challenge). On the available evidence, he is not an NPE/PAE-side specialist; he appears to work for operating companies on both enforcement and defense, and the tracked plaintiff-side count is too small to support a stronger characterization.

Firm context. He has spent essentially his entire career at Kellogg, Hansen, Todd, Figel & Frederick (now styled Kellogg Huber Hansen Todd Evans Figel), joining shortly after the firm's 1993 founding and becoming a partner in 2000. He also leads the firm's telecommunications research group. No prior firm history is reflected in the sources reviewed.

Notable cases and outcomes. The Regeneron matter is the most prominent tracked case and has resolved: per Sandoz's September 9, 2025 announcement and contemporaneous reporting (Pearce IP, Big Molecule Watch, Fierce Pharma), the parties settled all U.S. patent disputes, with dismissal entered in the N.D. West Virginia and Sandoz permitted to launch Enzeevu (aflibercept-abzv) in Q4 2026 or earlier in certain circumstances. Reporting on the case identified Leo as part of Regeneron's trial team alongside Williams & Connolly and other Kellogg Hansen lawyers. Also notable on his firm bio: the Corning ITC patent enforcement win, and the successful defense of Meta's Within Unlimited acquisition against the FTC's preliminary injunction request. He is credited by his firm as part of the trial team in FTC v. Meta Platforms (D.D.C. 2025), where the court entered judgment for Meta.

PTAB / IPR. I could not verify a regular IPR/PGR practice from firm materials, court opinions, or Law360/Reuters coverage; a commercial analytics profile shows a PTAB ranking but no underlying proceedings were confirmed, so this should be treated as unverified.

Bar / education. Admitted in New York (1994) and the District of Columbia (1996); J.D. with honors, George Washington University Law School (1993); B.A., UCLA (1990), per his firm biography.

Caveat on sourcing: the "17 communications cases / 12 computer architecture" breakdown comes from a third-party aggregator rather than a court record, and I found no Law360 or Reuters coverage specific to his individual patent results beyond the Regeneron settlement and the firm-level ITC and Meta matters.